Aims: Linezolid, the first available agent of a new antimicrobial class, the oxazolidinones, is broadly effective against drug-resistant gram-positive pathogens which are common causes of infections in hospitalized patients. However, it is not widely available in Malaysian government hospitals and therefore, relatively little is known about the prevalence of linezolid resistance in this background. The main aim of our study was to determine the prevalence of linezolid resistance among a total of 100 strains of methicillin-resistant Staphylococcus aureus (MRSA) isolated in June-October 2012 from two Malaysian state hospitals, namely Hospital Universiti Sains Malaysia (HUSM) and Hospital Pulau Pinang (HPP). The antibiotic susceptibility of the strains was also determined.
INTRODUCTION
MRSA is a worrisome pathogen in nosocomial infections in developing countries including Malaysia. Hospital Kuala Lumpur (HKL), which is the largest government tertiary referral hospital in the country, records an annual average of 40% MRSA prevalence (Ghaznavi-Rad et al., 2010) . The empiric treatment of choice for MRSA infections, socalled 'conventional' treatment, has been parenteral vancomycin. Although most MRSA strains are susceptible to vancomycin, a patient who is administered the drug requires serum trough (pre-dose) vancomycin concentration to be monitored every 12 h due to vancomycin's narrow therapeutic range. Vancomycin trough monitoring has been recommended as the most accurate and practical method to monitor this antibiotic and as a surrogate marker for the area under curve (AUC) pharmacokinetic parameter. A trough concentration range of 15-20 µg/mL is targeted as the lowest level of vancomycin present in the body (Rybak et al., 2009) . In patients who have renal impairment or have fluctuating volumes of distribution, such narrow concentrations are often difficult to attain. Furthermore, nephrotoxicity has been associated with high doses of vancomycin (Lodise et al., 2008) . The emergence of vancomycin intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA), though relatively uncommon, poses an additional challenge to the use of vancomycin (Ahmad et al., 2010) . Genome sequence comparison of all available VRSA Clonal Cluster 5 (CC5) strains isolated from the 12 documented cases of VRSA in the United States of America since 2002 show that these strains possess a constellation of traits that position them for acquiring resistance to antibiotics in mixed infections (Kos et al., 2012) . Hence the emergence of such superstrains with enhanced virulence poses a severe threat to our limited antibiotic arsenal and may lead to poor clinical outcomes.
The Infectious Diseases Society of America recommends that an alternative to vancomycin be used for MRSA isolates with a vancomycin MIC >2 µg/mL (Liu The aim of our study was to investigate the prevalence of linezolid resistance among MRSA isolates from the largest state tertiary referral hospitals in two geographic areas: one being the West coast state of Penang (Hospital Pulau Pinang [HPP] ) and the other, the East coast state of Kelantan (Hospital Universiti Sains Malaysia [HUSM] ). We also explored the multidrugresistance of these Malaysian nosocomial isolates. By gathering in vitro evidence which may support the use of alternative therapies, specifically linezolid, within the Malaysian hospital setting, we hoped to provide information for the development of guidelines for the rational use of medicines. (Liu et al., 2011) .
MATERIALS AND METHODS

Malaysia is a Southeast
S. aureus ATCC 33591 and ATCC 25923 were used as the MRSA and MSSA control strains respectively. To determine antimicrobial susceptibility, the Epsilometer test (Etest) was performed using Liofilchem  (Italy) antibiotic strips. Breakpoints for defining susceptibility categories for linezolid as well as 5 other drugs, selected on the basis of representation of different antibiotic classes and their antimicrobial activity against S. aureus, namely, chloramphenicol, clindamycin, erythromycin, oxacillin and vancomycin, were interpreted according to the criteria of the Clinical and Laboratory Standards Institute (CLSI, 2013). Vancomycin was included in the antimicrobial susceptibility testing since its MIC determination is not routinely carried out on clinical isolates of MRSA unless requested by the clinicians when their patients do not respond to treatment. Hence, we also wanted to determine the distribution of vancomycin MIC values among the MRSA isolates in our study hospitals and to identify putative VRSA and/or VISA strains. The study was approved by the National Institutes of Health for conducting research in the Ministry of Health Malaysia (NMRR-11-1093-8876). Figure 1 provides the average MICs for 18 MRSA isolates from HUSM and 82 MRSA isolates from HPP. All 100 strains were sensitive to linezolid with an average MIC of 0.71 µg/mL. The MICs for the current mainstay treatment for MRSA infections in these institutions, vancomycin, averaged at 1.13 µg/mL. Overall, a 2-to 3-fold greater potency of linezolid versus vancomycin was observed although vancomycin still retained activity against the MRSA isolates from both hospitals. While acknowledging that the number of isolates tested from the two hospitals was not equal as a limitation of expedience sampling, we noted that the HPP isolates had average MICs which were slightly raised for all the antibiotics tested except for oxacillin. The HPP MRSA isolates had developed very high MICs against clindamycin (a lincosamide) and erythromycin (a macrolide) in particular. The likelihood of such cross-resistance due to MLSB phenotype (resulting from dimethylation of A2058 in 23S rRNA leading to macrolide, lincosamide and streptogramin B resistance) will need to be verified using erm PCR and D-test. The MICs for chloramphenicol (a phenicol) averaged at 5.06 µg/mL for HUSM isolates versus 16.1 µg/mL for HPP isolates, making this antibiotic moderately active for HUSM isolates and only intermediately effective against MRSA from HPP. a MICs of antibiotics were determined by the CLSI method where sensitive (S), intermediate (I) and resistant (R) breakpoints in g/mL is as follows: linezolid (S4; 4<I>7; R8), vancomycin (S2; 2<I>16; R16), chloramphenicol (S8; 8<I>32; R32), clindamycin (S0.5; 0.5<I>4; R4), erythromycin (S0.5; 0.5<I>8; R8) and oxacillin (S2; 2<I>4; R4). In terms of overall resistance, as expected, all isolates were resistant to oxacillin. Thirtythree percent of the isolates were resistant to erythromycin while 20% were resistant to clindamycin. On the other hand, only 4% of all isolates were resistant to chloramphenicol. Three of the isolates, all originating from HPP, showed intermediate resistance to vancomycin with MICs ranging from 3-8 µg/mL. All of the 100 isolates were fully susceptible to linezolid. The in vitro linezolid susceptibility of the MRSA isolates suggests the absence of linezolid resistance mechanisms. Further testing of this hypothesis is currently under investigation. Although all 100 MRSA isolates appear to be susceptible to linezolid by standard susceptibility test methods, clinical linezolid treatment failure may still be possible especially in a heterogeneously resistant isolate (Ikeda-Dantsuji et al., 2011) . A recent study on 50 linezolid-resistant staphylococcal isolates from Italy showed cross-resistance to erythromycin, lincomycin, levofloxacin, gentamicin, cotrimoxazole and teicoplanin (Campanile et al., 2013) . Combined resistance to phenicols, macrolides and lincosamides may have a synergistic effect on linezolid resistance since all these drugs have overlapping drug binding sites on the large ribosomal subunit (Schlunzen et al., 2001; Leach et al., 2007) . Our MRSA isolates did indeed show a multidrugresistant MDR profile [defined as acquired nonsusceptibility to at least one agent in three or more antimicrobial categories (Magiorakos et al., 2012) . In fact, 25.6% of the HPP isolates (21/82) were multiple antibiotic resistant while only one of the oxacillin-resistant HUSM isolates was additionally resistant to erythromycin, making all 18 HUSM isolates non-MDR ( (Figure 3 ). The elucidation of the underlying resistance genes or mechanisms of multidrug-resistance is currently under investigation. The highly probable co-existence of such resistance determinants in our MDR strains of MRSA imply that linezolid-resistant strains may be very easily co-selected, especially under antibiotic pressure.
RESULTS AND DISCUSSION
CONCLUSION
Even though the best alternative antibiotic choice is not a resolved issue, insight into the prevalence of resistance is invaluable for strategic MRSA pathogenic control. In all 100 clinical isolates from 2 Malaysian hospital sites, complete susceptibility to linezolid was found, and the results of the study provide the basis for the use of oxazolidinone therapies to address possible emerging vancomycin resistance among Malaysian hospitalacquired MRSA strains. The presence of cross-resistance to four classes of antibiotics in the MRSA isolates multiplies the risk of co-selection of linezolid-resistant strains. Additional surveillance studies are clearly warranted in order to monitor the emergence of linezolid resistance in Malaysia.
